A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Sponsor

Daiichi Sankyo, Inc. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05400369

Collaborator

(none)

268

Enrollment

Locations

Arms

10.6

Anticipated Duration (Months)

22.3

Patients Per Site

2.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation.

Acute exacerbation, especially frequent exacerbation, is associated with an increased risk of death in COPD patients. The most common causes of acute attacks are viral and bacterial infections.

This study will assess the efficacy and safety of sitafloxacin, a quinolone antibacterial drug, in participants with AECOPD.

Condition or Disease	Intervention/Treatment	Phase
COPD Exacerbation Acute	Drug: Sitafloxacin Drug: Moxifloxacin Hydrochloride	Phase 4

Detailed Description

Clinical evidence suggests that AECOPD may be an important factor in the cause of death in patients with COPD. AECOPD typically presents with increased dyspnea, cough, and sputum volume, or purulent changes in sputum. The most common factors of AECOPD are viral and bacterial infections. Anti-infection agents have shown to be effective in patients with infectious AECOPD.

This study will assess the anti-bacterial drug sitafloxacin in participants with AECOPD. Clinical efficacy is the primary objective of the study. Microbiological validity, symptom relief, magnitude of change in symptom score and inflammatory biomarker, and recurrence rate and safety will also be assessed.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

268 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Anticipated Study Start Date :

Aug 5, 2022

Anticipated Primary Completion Date :

Jun 23, 2023

Anticipated Study Completion Date :

Jun 23, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Sitafloxacin Adult participants who will be randomized to receive 100 mg sitafloxacin (2 tablets) orally once a day.	Drug: Sitafloxacin Oral administration, 50 mg tablets Other Names: Gracevit
Active Comparator: Moxifloxacin Adult participants who will be randomized to receive 400 mg moxifloxacin (1 tablet) orally every 24 hours.	Drug: Moxifloxacin Hydrochloride Oral administration, 400 mg tablets Other Names: Avelox

Arm

Intervention/Treatment

Experimental: Sitafloxacin

Adult participants who will be randomized to receive 100 mg sitafloxacin (2 tablets) orally once a day.

Drug: Sitafloxacin

Oral administration, 50 mg tablets

Other Names:

Gracevit

Active Comparator: Moxifloxacin

Adult participants who will be randomized to receive 400 mg moxifloxacin (1 tablet) orally every 24 hours.

Drug: Moxifloxacin Hydrochloride

Oral administration, 400 mg tablets

Other Names:

Avelox

Outcome Measures

Primary Outcome Measures

Number of Participants Achieving Clinical Efficacy in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease [End of treatment (approximately Day 10 post-dose)]
Clinical efficacy is divided into clinical cure and clinical ineffective. Clinical cure is defined as the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) that disappear or return to the baseline level of stable phase at the end of treatment/discontinuation and no additional systemic antibacterial therapy is required for the target indication. Clinical ineffective is defined as the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) that persist or incompletely disappear (do not return to the baseline level of stable phase).

Secondary Outcome Measures

Number of Participants Achieving Clinical Efficacy in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease [1 month post-dose]
Clinical efficacy is divided into clinical cure and clinical ineffective. Clinical cure is defined as the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) that disappear or return to the baseline level of stable phase at the end of treatment/discontinuation and no additional systemic antibacterial therapy is required for the target indication. Clinical ineffective is defined as the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) that persist or incompletely disappear (do not return to the baseline level of stable phase).
Number of Participants Achieving Microbiological Efficacy in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease [End of treatment (approximately Day 10 post-dose)]
Microbiological efficacy is determined by bacterial clearance: Clearance is defined as specimens from the original infection site after treatment do not culture pathogenic bacteria from the original infection.
Number of Days With Symptom Relief in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease [From the start of treatment up to relief of three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence), up to 1 month post-dose]
The number of days with symptom relief of the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) will be assessed.
Change from Baseline in Each Chronic Obstructive Pulmonary Disease Symptom Score in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease [End of treatment (approximately Day 10 post-dose)]
Chronic obstructive pulmonary disease symptom scores include dyspnea (ranging from 0 [Dyspnea only with strenuous activity] to 4 [Unable to leave home due to severe respiratory distress, or dyspnea when wearing and undressing]), sputum volume (ranging from 0 [no sputum] to 3 [severe]), sputum purulence (ranging from 0 [myxoid sample] to 3 [severe purulent]), cough score (ranging from 0 [no cough] to 3 [severe cough]), fever (ranging from 0 [≤37.0°C] to 3 [>38.0°C], and COPD Assessment Test (CAT) (where questions 1-8, range from a score of 0 [no impact] to 5 [severely impacted]. For all assessments, higher scores indicate worse outcome.
Change from Baseline in Inflammatory Biomarker C-reactive Protein in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease [End of treatment (approximately Day 10 post-dose)]
Recurrence Rate of Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease [End of treatment (approximately Day 10 post-dose) up to 1 month post-dose]
Recurrence rate is defined as when the clinical outcome of the participant at the end/discontinuation of treatment is determined to be clinically cured, but AECOPD occurs again within 20 days after drug withdrawal due to incomplete anti-infective treatment, the participant develops one or more of the three main symptoms of worsening dyspnea, increased phlegm production, and sputum production, and also has relevant signs of AECOPD, with repeated blood routine, C-reactive protein and other inflammatory indicators, and needs to receive systemic antibacterial drug treatment again, and the pathogenic bacteria belonged to the same strain and serotype as the bacteria originally infected.

Eligibility Criteria

Criteria

Ages Eligible for Study:

40 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age ≥ 40;
History of moderate to very severe COPD with a post-bronchodilator Forced Expiratory Volume in One Second/Forced Vital Capacity (FEV1/FVC) < 70% and a post-bronchodilator Forced Expiratory Volume in One Second (FEV1) < 80% of predicted normal value within one year prior to enrollment;
History of one or more acute exacerbations within one year prior to enrollment;
At least 6 weeks of stable disease prior to enrollment;
The acute exacerbation is classified as Anthonisen I (with 3 main symptoms of worsening dyspnea, increased sputum volume and sputum purulence) or II (with sputum purulence and another main symptom);
Participants can be treated on an outpatient basis after clinical assessment.

Exclusion Criteria:

Anthonisen III acute exacerbation (Have two major symptoms of worsening dyspnea and increased sputum volume or one of the two major symptoms)
Hospitalization or intensive care unit (ICU) treatment is required
Sputum culture within the previous year indicated the presence of pathogenic microorganisms resistant to quinolones
Quinolone allergy
History of QTc prolongation, or need for medications to treat QTc prolongation (e.g., Class Ia or Class III antiarrhythmics);
Definite pulmonary disease other than COPD (asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism, pulmonary fibrosis, lung cancer)
History of severe cardiovascular disease (e.g., congestive heart failure, clinically significant coronary heart disease, stroke, myocardial infarction and/or stroke within 6 months, clinically significant arrhythmia, previous history of aortic aneurysm or aortic dissection, positive family history, or risk factors (e.g., Marfan syndrome), poorly controlled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg on 2 or more consecutive measurements)
Severe systemic diseases, such as severe dizziness, headache and other nervous system diseases
Malignant tumor
Concomitant or history of tendon disease or myasthenia gravis or Parkinson's disease
Abnormal liver function, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) level > 3 times the upper limit of normal, and/or total bilirubin level >2 times the upper limit of normal
With moderate or severe decline of renal function, endogenous creatinine clearance rate (Ccr) < 50ml/min
History of seizure, or psychiatric condition that could affect compliance with the protocol, or risk for suicide, or history of alcohol or illicit drug abuse
Immunocompromised participants using glucocorticoids (total dose equivalent to prednisone 20 mg daily for more than 2 weeks) or immunosuppressive agents or HIV infected participants
Gastrointestinal disorders that may affect drug absorption (e.g., active Crohn's disease, active ulcerative colitis)
Pregnant or lactating women or women of childbearing potential who are planning to become pregnant
Participation in other clinical trials within 3 months prior to screening
Used antibiotics (including systemic and inhalation) 30 days before enrollment
Serum potassium < 3.5mmol/L at screening, or repeated hypokalemia that was difficult to correct in the past
Other reasons that the investigator considered inappropriate to participate in the study.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	The Third Xiangya Hospital of Central South University	Changsha	China	410013
2	West China Hospital Sichuan University	Chengdu	China	610041
3	Nanfang Hospital Southern Medical University	Guangzhou	China	510510
4	Qilu Hospital of Shandong University	Jinan	China	250012
5	Peking University Shougang Hospital	Peking	China	100144
6	Huadong Hospital Affiliated To Fudan University	Shanghai	China	200433
7	Shenzhen People's Hospital	Shenzhen	China	518140
8	Tianjin Medical University General Hospital	Tianjin	China	300070
9	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	430030
10	The Affiliated Hospital of Xuzhou Medical University	Xuzhou	China	221004
11	Affiliated Hospital of Guangdong Medical University	Zhanjiang	China	523710
12	Henan Provincial People's Hospital	Zhengzhou	China	450003